These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 25042800)
21. Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder. Cheng L; Lopez-Beltran A; Wang M; Whaley RD; De Souza A; Au S; Ge R; Cimadamore A; Amin A; Golijanin B; MacLennan GT; Osunkoya AO; Montironi R; Zhang S Mod Pathol; 2023 Jul; 36(7):100151. PubMed ID: 36906071 [TBL] [Abstract][Full Text] [Related]
22. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487 [TBL] [Abstract][Full Text] [Related]
23. TERT promoter mutations in penile squamous cell carcinoma: high frequency in non-HPV-related type and association with favorable clinicopathologic features. Kim SK; Kim JH; Han JH; Cho NH; Kim SJ; Kim SI; Choo SH; Kim JS; Park B; Kwon JE J Cancer Res Clin Oncol; 2021 Apr; 147(4):1125-1135. PubMed ID: 33635430 [TBL] [Abstract][Full Text] [Related]
24. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. Cowan M; Springer S; Nguyen D; Taheri D; Guner G; Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Cunha I; Fujita K; Ertoy D; Bivalacqua TJ; Kinzler K; Vogelstein B; Netto GJ; Papadopoulos N Mod Pathol; 2016 May; 29(5):511-5. PubMed ID: 26965579 [TBL] [Abstract][Full Text] [Related]
25. Benign and Malignant Brenner Tumors Show an Absence of TERT Promoter Mutations That Are Commonly Present in Urothelial Carcinoma. Khani F; Diolombi ML; Khattar P; Huang W; Fallon JT; Epstein JI; Zhong M Am J Surg Pathol; 2016 Sep; 40(9):1291-5. PubMed ID: 27299795 [TBL] [Abstract][Full Text] [Related]
26. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. Chang KP; Wang CI; Pickering CR; Huang Y; Tsai CN; Tsang NM; Kao HK; Cheng MH; Myers JN Head Neck; 2017 Jun; 39(6):1131-1137. PubMed ID: 28230921 [TBL] [Abstract][Full Text] [Related]
27. Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population. Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Siraj N; Siraj S; Diaz MRF; Rala DR; Benito AD; Sabido MA; Al-Rasheed M; Al-Obaisi KAS; Al-Haqawi W; Victoria IG; Al Balawy W; Abedalthagafi M; Wakil SM; Ajarim D; Mohammed S; Alhussain T; Tulbah A; Al-Badawi IA; Al-Dayel F; Al-Kuraya KS Genomics; 2020 Mar; 112(2):1746-1753. PubMed ID: 31669704 [TBL] [Abstract][Full Text] [Related]
28. Comparative study of TERT promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma. Brown NA; Lew M; Weigelin HC; Weizer AZ; Montgomery JS; Betz BL; Mehra R Histopathology; 2018 Jan; 72(2):354-356. PubMed ID: 28741734 [No Abstract] [Full Text] [Related]
29. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma. Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605 [TBL] [Abstract][Full Text] [Related]
31. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas. Vinothkumar V; Arunkumar G; Revathidevi S; Arun K; Manikandan M; Rao AK; Rajkumar KS; Ajay C; Rajaraman R; Ramani R; Murugan AK; Munirajan AK Tumour Biol; 2016 Jun; 37(6):7907-13. PubMed ID: 26700669 [TBL] [Abstract][Full Text] [Related]
32. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Cowan ML; Springer S; Nguyen D; Taheri D; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; Del Carmen Rodriguez Pena M; VandenBussche CJ; Olson MT; Cunha I; Fujita K; Ertoy D; Kinzler K; Bivalacqua T; Papadopoulos N; Vogelstein B; Netto GJ Hum Pathol; 2016 Jul; 53():8-13. PubMed ID: 26980028 [TBL] [Abstract][Full Text] [Related]
33. TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. Mannan R; Taylor AS; Spratt DE; Chinnaiyan AM; Montgomery JS; Brown NA; Mehra R Pathol Res Pract; 2020 Jan; 216(1):152663. PubMed ID: 31630874 [TBL] [Abstract][Full Text] [Related]
34. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region. Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798 [TBL] [Abstract][Full Text] [Related]
35. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525 [TBL] [Abstract][Full Text] [Related]
36. Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma. Annunziata C; Pezzuto F; Greggi S; Ionna F; Losito S; Botti G; Buonaguro L; Buonaguro FM; Tornesello ML Int J Cancer; 2018 Sep; 143(5):1153-1161. PubMed ID: 29603728 [TBL] [Abstract][Full Text] [Related]
37. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. Cevik D; Yildiz G; Ozturk M World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106 [TBL] [Abstract][Full Text] [Related]
38. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study. Hosen MI; Sheikh M; Zvereva M; Scelo G; Forey N; Durand G; Voegele C; Poustchi H; Khoshnia M; Roshandel G; Sotoudeh M; Nikmanesh A; Etemadi A; Avogbe PH; Chopard P; Delhomme TM; Foll M; Manel A; Vian E; Weiderpass E; Kamangar F; Boffetta P; Pharaoh PD; Dawsey SM; Abnet CC; Brennan P; McKay J; Malekzadeh R; Calvez-Kelm FL EBioMedicine; 2020 Mar; 53():102643. PubMed ID: 32081602 [TBL] [Abstract][Full Text] [Related]
39. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513 [TBL] [Abstract][Full Text] [Related]
40. Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer. Zvereva M; Hosen MI; Forey N; Sheikh M; Kannengiesser C; Ba I; Manel A; Vian E; Le Calvez-Kelm F Methods Mol Biol; 2023; 2684():213-228. PubMed ID: 37410237 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]